Terminated NA INTERVENTIONAL 1-arm NCT00005786

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia

A Pilot Study of Arsenic Trioxide in the Treatment of Relapsed and Refractory Indolent Lymphomas

Sponsor: National Cancer Institute (NCI)

Conditions Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Nodal Marginal Zone B-cell Lymphoma Prolymphocytic Leukemia Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Splenic Marginal Zone Lymphoma Waldenström Macroglobulinemia

Interventions arsenic trioxide laboratory biomarker analysis

Updated 6 times since 2017 Last updated: Jan 31, 2013 Started: Jan 31, 2001 Primary completion: Nov 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Administratively complete.

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Other Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue trials with similar outcome

Browse all Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue trials

Listed as NCT00005786, this NA trial focuses on Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue and Nodal Marginal Zone B-cell Lymphoma and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated NA
Jul 2024 — Sep 2024 [monthly]

Terminated NA
Jan 2021 — Jul 2024 [monthly]

Terminated NA
Jun 2018 — Jan 2021 [monthly]

Terminated NA
Feb 2017 — Jun 2018 [monthly]

Terminated NA

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated NA

First recorded

Jan 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States